127942-30-7

Basic information

• Product Name: ETHYL 2-AMINOTHIAZOLE-4-CARBOXYLATE
• Synonyms: 4-THIAZOLECARBOXYLIC ACID, 2-AMINO-, ETHYL ESTER;AKOS BBV-000509;ETHYL-2-AMINOTHIAZOLE-4-CARBOXYLIC ACID;2-Aminothiazole-4-carboxylic acid ethyl ester hydrobromide;2-Aminothiazole-4-carboxylic acid ethyl ester monohydrobromide;ETHYL 2-AMINOTHIAZOLE-4-CARBOXYLATE hcl;ethyl 2-aMinothiazol-4-carboxylate HBr;2-Amino-4-(ethoxycarbonyl)-1,3-thiazole hydrobromide
• CAS NO: 127942-30-7
• Molecular Formula: C6H8N2O2S
• Molecular Weight: 0
• Mol File: 127942-30-7.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: ETHYL 2-AMINOTHIAZOLE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-AMINOTHIAZOLE-4-CARBOXYLATE(127942-30-7)
• EPA Substance Registry System: ETHYL 2-AMINOTHIAZOLE-4-CARBOXYLATE(127942-30-7)

Safety Data

• Hazardous Substances Data: 127942-30-7(Hazardous Substances Data)

Usage

General Description

ETHYL 2-AMINOTHIAZOLE-4-CARBOXYLATE is a chemical compound that consists of a thiazole ring with an amino group and a carboxylate group attached to it. It is commonly used in the synthesis of pharmaceuticals and agrochemicals, serving as a building block for the production of various bioactive molecules. ETHYL 2-AMINOTHIAZOLE-4-CARBOXYLATE has also been studied for its potential biological activities, including antimicrobial, antifungal, and anti-inflammatory properties. Additionally, it has been investigated for its potential use in the development of new materials and catalysts. Overall, ETHYL 2-AMINOTHIAZOLE-4-CARBOXYLATE is a versatile compound with various applications in the fields of chemistry, medicine, and materials science.

Upstream product

• 70-23-5 ethyl Bromopyruvate 
• 17356-08-0 thiourea 
• 1378831-76-5 ethyl bromopyruvate 
• 62-56-6 thiourea 

Downstream Products

• 232596-68-8 ethyl 2-phenoxycarbonyl-amino-thiazole-4-carboxylate 

Relevant articles and documents

Soluble head-to-tail regioregular polythiazoles: Preparation, properties, and evidence for chain-growth behavior in the synthesis via Kumada-Coupling polycondensation

Head-to-tail regioregular poly(4-alkylthiazole)s containing silylethers in the side-chains were synthesized via Kumada-Coupling polycondensation of "reversed" monomers, that were metalated at the sterically hindered 5-position. Their optical, electrochemi

Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema

Vascular adhesion protein-1 (VAP-1), an amine oxidase that is also known as a semicarbazide-sensitive amine oxidase (SSAO), is present in particularly high levels in human plasma, and is considered a potential therapeutic target for various inflammatory diseases, including diabetes complications such as macular edema. In our VAP-1 inhibitor program, structural modifications following high-throughput screening (HTS) of our compound library resulted in the discovery that thiazole derivative 10, which includes a guanidine group, shows potent human VAP-1 inhibitory activity (IC50 of 230 nM; rat IC 50 of 14 nM). Moreover, compound 10 exhibited significant inhibitory effects on ocular permeability in STZ-induced diabetic rats.

SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES

Described herein are antipyschotic compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; R1 is hydrogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, -CN, imidazolidin-2-one, phenyl, or tetrazole wherein tetrazole is unsubstituted or substituted with (C1-4) alkyl; R2 is H, halogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, OR6, SR6, NO2, CN, COR6, C(O)OR6, C(OH)R6, CONR7R8, phenyl or (C1-6) alkyl, wherein the (C1-6) alkyl is unsubstituted or substituted with a hydroxy; R3 is hydrogen, (C 1-6)fluoroalkyl , (C3-6) cycloalkyl, (C2-6) alkenyl, phenyl, monocyclic heteroaromatic, bicyclic heteroaromatic, or (C1-4)alkyl wherein (C1-4) alkyl is unsubstituted or substituted with a phenyl; R4 and R5 are independently selected from hydrogen, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR9, SR9, NO2, CN, or COR9; R6 is hydrogen, (C1-6) fluoroalkyl, or (C1-6) alkyl; R7 and R8 are independently hydrogen, or (C1-6) alkyl; R9 is hydrogen, (C1-6) fluoroalkyl, (C1-6) alkyl; Alk is (C1-4) alkylene unsubstituted or substituted with a hydroxy; Y is oxygen, sulfur, SO2, or a bond; X is CH2, C=O, S, O, or SO2; Z is hydrogen, halogen, (C1-6) alkyl, (C1-6)fluoroalkyl, -OH, (C1-6) alkoxy, (C1-6) fluoroalkoxy, (C1-6) alkylthio, (C1-6) acyl, (C1-4)alkylsulfonyl, -OCF3, -NO2, - CN, carboxamido which may be substituted on the nitrogen by one or two (C1-4) alkyl groups, and -NH2 in which one of the hydrogens may be replaced by a (C1-4) alkyl group and the other hydrogen may be replaced by either a (C1-4) alkyl group, a (C1-6) acyl group, or a (C1-4) alkylsulfonyl group; the phenyl of R1, R2 or R3 is independently unsubstituted or substituted with one to three substituents independently selected from Z; the monocyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; the bicyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; and salts, solvates, and crystal forms thereof. Also described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).